Previous Page  4 / 18 Next Page
Show Menu
Previous Page 4 / 18 Next Page
Page Background

Volume 6, Issue 4(Suppl)

Transl Med 2016

ISSN: 2161-1025, an open access journal

Page 64




Translation Medicine & World Oncologists 2016

November 28-30, 2016

Translational Medicine and Oncologists Meet

November 28-30, 2016 San Francisco, USA



Annual Conference on

Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma

Bing Zhu

The first Affiliated Hospital of Bengbu Medical College, China


Chemokines have been recognized as important modulators of angiogenesis and they play critical roles in the

development and metastasis of hepatocellular carcinoma (HCC), although their origins and latent molecular mechanisms remain



The aim of this study was to investigate how activated hepatic stellate cells (a-HSCs) promote angiogenesis in HCC.


A total of 22 HCC patients were enrolled randomly. We used immunohistochemistry; western blotting and enzyme-linked

immunosorbent assay (ELISA) to analyze the production of interleukin-8 (IL-8) in a-HSCs derived fromHCC tissues. The angiogenic

effects of IL-8 in vitro and in vivo were assessed by ELISA, real-time quantitative polymerase chain reaction, capillary tube formation

assay and chick embryo chorioallantoic membrane assay.


The present study showed that IL-8 was enriched predominantly in the tumor stroma of HCC tissues and was mainly

derived from a-HSCs, rather than from hepatoma cells, in vivo and in vitro. Angiogenesis was most active at the invading edge, which

was close to the a-HSCs. The angiogenic effect was dramatically attenuated by an IL-8 neutralizing antibody both in vitro and in

vivo. Moreover, the IL-8 neutralizing antibody down-regulated Ser727-phosphorylated STAT3 levels in hepatoma cells treated with

a-HSCs conditioned medium.


These findings reveal that a-HSCs within the stroma of HCC contribute to tumor angiogenesis via IL-8.


Bing Zhu is a Doctor and has more than 10 years of experience in General Surgery department. He has completed his PhD from Zhongshan University's third affiliated

hospital. Currently, his major directions of research are Tumor Angiogenesis.

[email protected]

Bing Zhu, Transl Med 2016, 6:4(Suppl)